Navigation Links
Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
Date:8/4/2010

IPSWICH, Mass., Aug. 4 /PRNewswire/ -- New England Biolabs is pleased to announce that Canada's Michael Smith Genome Sciences Center has selected New England Biolabs as one of its key suppliers for next-generation sequencing library construction reagents. NEBNext DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited and validated for sample preparation for next generation sequencing, as well as the preparation of expression libraries. Reagents are available for each step of the library construction workflow, and are compatible with the Illumina® GAII and HiSeq2000, Roche/454 GS FLX Titanium and LIFE SOLiD 4 sequencing platforms. These sets are highly cost effective and each of the components must pass rigorous quality control and functional validation before release.

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b )

About New England Biolabs (NEB)

Established in mid 1970s, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis and RNA analysis. Additionally, NEB is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.

About the Michael Smith Genome Sciences Center

The Genome Sciences Centre has a primary mandate to deploy resources and technology of a high-throughput genome mapping and DNA sequencing lab to decrypt the genetic code, specifically to advance cancer research, diagnosis and treatment.

Combining the experience of world-renowned scientists, the GSC plays a major role in the fields of genomics and bioinformatics as well as various genome projects around the world. The priority of the centre is to find innovative means to automate the sequencing and fingerprinting process, develop cost-effective measures that will make such research financially viable and utilize state-of-the-art computing facilities to collect, mine, analyze and disperse data collected at this and other genome facilities.

Illumina is a registered trademark of Illumina, Inc.

GS FLX Titanium is a trademark of Roche.

SOLiD is a trademark of Life Technologies.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Garippa Joins SynCardia as President
2. 2010 Michael E. DeBakey Journalism Awards Announced
3. Michael Youssef Offers Insight into the Muslim Perspective on Oil and the World Economy
4. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
5. Michael Sitaras of SavATree Earns ISA Certified Arborist Designation
6. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
7. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
8. Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
9. Oxford BioTherapeutics Appoints Michael Moore as Chairman
10. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
11. Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):